Cellectis Annual Shareholders Meeting Set for June 25, 2026
Cellectis, a clinical-stage biotechnology company developing a gene-editing platform, has announced its 2026 annual general meeting will take place on June 25. The meeting is scheduled for Paris.
Cellectis, a biotechnology company focused on gene editing for cell and gene therapies, has announced that its annual shareholders general meeting will convene on June 25, 2026. The meeting is scheduled to begin at 2:30 p.m. CET at the Biopark auditorium in Paris.
This announcement, made on May 20, 2026, sets the date for the company's yearly gathering of its shareholders. Cellectis utilizes its gene-editing platform to develop treatments.
The official notice of the meeting, which will include the agenda and voting procedures, is available on the Cellectis investor relations website.